All too often, software patents stop more innovation than they promote. Patents are legal instruments that can be used to sue people and companies for creating, selling, or using software. Very often, the entities wielding software patents are patent trollscompanies that make money off suing and threatening to sue others instead of building or doing anything of their own.
Weve been advocating against problematic patents, particularly in software, for many years. In the past few years, its fair to say that patent trolls have been downbut not out. Two big changes that happened several years ago have made it realistic, finally, to get bad patents kicked out of the system. The first is the creation of the inter partes review system, in 2012; and next, the Supreme Courts Alice v. CLS Bank decision, in 2014.
Unfortunately, 2019 has shown us that we need to keep working to protect the patent system. Congress and the U.S. Patent Office have been working remarkably hard to roll back these positive changes, and make life easier for patent trolls. At the same time, the Federal Circuit has been eroding the effect of Alice in decisions like last years in HP v. Berkheimer and this years Garmin v. Cellspin.
At the beginning of the year, USPTO Director Andre Iancu promulgated new guidance for patent examiners that essentially allows them to blow off the clear guidelines of the Alice decision. What that meant, in practice, is that examiners are being told to issue more of the worst type of software patentsones that simply take abstract ideas, and make them sound like an invention by adding generic computer language. That means more patents coming out that will be fodder for patent trolls.
At EFF, we encouraged people to let the Patent Office know that the new guidelines were a bad idea. While we werent able to stop the new guidelines from taking effect, our supporters sent more than 1,500 comments to the Patent Officesending a strong message that everyday users of technology are finally watching a government office that, all too often, is left in a state of total industry capture.
In the U.S. Senate, leaders of a newly reconstituted IP Subcommittee have pushed forward two ideas that threaten to bring back the bad old days of peak patent trolling. The first attempt to empower patent trolls is a year-long effort to undermine Section 101 of the patent laws. Thats the section that bans patents on abstract ideas, natural phenomenon, and laws of nature. Its the area of law that the Supreme Court properly interpreted in the Alice case, and in recent years, has allowed courts to throw hundreds of junk patents out of the system.
Senators Thom Tillis (R-N.C.) and Chris Coons (D-Del.) have insisted that Section 101 has stopped good inventions from getting patents. Thats not true. Many of the parties asking Congress to alter Section 101 are flat-out patent trolling entities, who dont invent any technology themselvestheyre simply good at manipulating the patent system and threatening lawsuits. Others are large incumbent companies with massive patent portfolios, like GlaxoSmithKline, Qualcomm, and IBM. These companies simply want more monopolies on areas of emerging technology, like artificial intelligence and personalized medicine.
At EFF, we spoke out against this misguided effort, and EFF Staff Attorney Alex Moss testified in front of Congress. In the end, no bill to damage Section 101 has yet been introduced. Thats a testament to the advocacy of EFF and our many allies on this issue. But well have to stay vigilant on this front, since theres no doubt the same groups, seeking to wring more money from the patent system, will be back again in 2020. Fortunately, were able to work together with a huge range of alliesnot just tech companies that want a balanced patent system, but also health care providers, labor unions, and consumer organizations.
Another perennial bad idea that returned in 2019 was the Stronger Patents Act, which would do a great job of strengthening patent trolls but offers nothing to true innovators. The Stronger Patents Act would have essentially wrecked inter partes review, or IPR, which is one of the most effective ways of challenging patents. Were glad to report this bill went nowhere, and hope we dont see it again.
Patent trolls continue to seek unjustified payments from companies of all sorts, many of them small firms that cant afford the million-dollar legal bills that would come with a patent trial. Just one example: a patent troll called Inventergy sued a family-owned GPS tracking company, along with several other GPS firms. Inventergy backed off once we sent a letter explaining the problems with its patent, and EasyTracGPS has become one of the firms that was Saved by Alice.
Another great example is Ruth Taylor, who was sued over her website that organized online photography contests. We helped Ruth win her patent case back in 2015. This year, we published a video interview with Ruth talking about her experience, facing down a patent trolls demand for $50,000 over her hobby website.
EFF scored a big win for transparency in the patent system when we intervened in a lawsuit filed by Uniloc, one of the most litigious patent trolls of all time, in court. Uniloc has sued dozens of technology companies, but at the same time has kept much of its most important pleadings redacted. But when Uniloc sued Apple, documents emerged that seemed to indicate Uniloc may not have rights to the patent it was asserting, because it had split the rights with a murky patent investment fund. EFF intervened to demand that the redacted documents be published, so that the public can understand the nature of Unilocs far-ranging allegations.
In May, Uniloc definitively lost this attempt to hide its machinations and shell games from the public. Uniloc has chosen to appeal this case to the Federal Circuit, where well defend the publics First Amendment right of access to the courts.
Finally, 2019 saw a major win for patents and free speech. In New Hampshire, a patent troll called Automated Transactions, LLC sued more than a dozen people and a trade group claiming it was defamedsimply because these groups had described it as a patent troll. EFF filed an amicus brief arguing this term cant be defamatory. The New Hampshire Supreme Court agreed, finding that calling someone a patent troll is a statement of protected opinion, not fact.
In 2020, with our supporters help, well continue to litigate, and advocate, for a fairer and more balanced patent system. And, when we need to, well call a troll a trolland you can, too.
This article is part of our Year in Review series. Read other articles about the fight for digital rights in 2019.
DONATE TO EFF
LIKE WHAT YOU'RE READING? SUPPORT DIGITAL FREEDOM DEFENSE TODAY!
Read more:
Time to Save Alice: 2019 Year in Review - EFF
- Personalized medicine could transform healthcare - PMC - April 24th, 2025
- Genomic medicine and personalized treatment: a narrative review - April 24th, 2025
- Podcast: Ochre Bios Approach To Precision Medicine In Liver Treatment - insights.citeline.com - April 24th, 2025
- Reinforcement Learning in Personalized Medicine: A Comprehensive Review of Treatment Optimization Strategies - Cureus - April 24th, 2025
- Evolving Biomarkers: Charting the Future of Precision Medicine - MarketScale - April 24th, 2025
- Next Generation Tissue Biomarkers Market Size Report 2030 - Grand View Research - April 24th, 2025
- City of Hope Research on Artificial Intelligence (AI), Precision Medicine, Immunotherapies and Other Topics to be Presented at American Association of... - April 24th, 2025
- What the Newest mRNA Vaccines Could Do Beyond COVID - News-Medical - April 24th, 2025
- Opinion: Where public health ends and personalised medicine begins - Pulse+IT News - April 24th, 2025
- Crohns Disease Treatment Market to Reach $5.9 Billion by 2034, Driven by Biologics & Precision Medicine - Global Banking | Finance | Review - April 24th, 2025
- The Role of High Throughput Screening in Precision Medicine and Market Growth In New Report - WhaTech - April 24th, 2025
- Antiviral Chewing Gum May Prevent Flu and Herpes Transmission - Inside Precision Medicine - April 14th, 2025
- Wisconsin's role in the next advances in health care - BizTimes - April 14th, 2025
- The Future of Pulmonary Fibrosis Management: Precision Medicine, Biomarkers and AI - Managed Healthcare Executive - April 14th, 2025
- Leading Driver In The Jetrea Market 2025: Rise Of Personalized Medicine Fueling Growth - EIN News - March 9th, 2025
- Personalized Medicine Market Overview 2024-2025 & 2030: Oncology, Neurology, and Cardiology Lead Expansion, ext-Generation Sequencing and AI... - March 9th, 2025
- Innovations in core-shell nanoparticles advance drug delivery and precision medicine - Phys.org - March 9th, 2025
- Personalized Medicine: Motivation, Challenges and Progress - February 24th, 2025
- Healthcare innovations in predictive analytics, AI, and personalized medicine - HealthLeaders Media - February 24th, 2025
- Healthcare innovations in predictive analytics, AI, and personalized medicine - Fast Company - February 24th, 2025
- Artificial Intelligence (Ai) In Precision Medicine Market to See Robust Growth from USD 2.14 Billion to USD - EIN News - February 24th, 2025
- BMY: 3 Precision Medicine Stocks That Could Transform Healthcare - StockNews.com - February 24th, 2025
- Cracking Cancers Code: How Genetic Testing Is Changing the Treatment Game - geneonline - February 24th, 2025
- Curt Medeiros on Revolutionizing Precision Medicine and Scaling Ovation - Madrona Venture Group - January 6th, 2025
- Personalized medicine: The pros, cons and concerns - New Atlas - November 16th, 2024
- Precision Medicine, AI, and the Future of Personalized Health Care - November 16th, 2024
- Why precision medicine results in more effective health care, treatment plans - The Business Journals - November 16th, 2024
- Comprehensive Genomic Profiling at Diagnosis Extends Survival in Patients with Advanced Cancer - Inside Precision Medicine - November 16th, 2024
- More Precise Classifications of NonClear Cell RCC Are Required to Improve Personalized Treatment - OncLive - September 13th, 2024
- Bahrain aims to provide residents with personalized healthcare - Healthcare IT News - September 13th, 2024
- Precision Medicine Market Is Expected To Reach Revenue Of - GlobeNewswire - September 13th, 2024
- New Graduates Leverage Genomics Education in Clinical and Research Settings - University of Colorado Anschutz Medical Campus - June 20th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022